The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure Academic Article uri icon

Overview

MeSH Major

  • Endothelin Receptor Antagonists
  • Heart Failure
  • Pyridines
  • Tetrazoles

abstract

  • In patients admitted with AHF, tezosentan doses of 1-25 mg/h are efficacious in improving the hemodynamics and reducing BNP. Tezosentan doses beyond 1 mg/h increased plasma endothelin levels and reduced urine output, probably limiting their clinical efficacy, as compared to tezosentan 1 mg/h.

publication date

  • August 2004

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.ejheart.2004.05.004

PubMed ID

  • 15302008

Additional Document Info

start page

  • 601

end page

  • 9

volume

  • 6

number

  • 5